Hi Connie, sorry it may be a silly question but has he been exposed to oxaliplatin (eg via FOLFOX) before? This is a common first-line, along with FOLFIRI. Depending on some other factors an anti-VEGF drug such as Avastin (bevacizumab) may also often be considered.
Given he has been on Erbitux I presume he doesn’t have a RAS mutation... do you happen to know his MSS status and/or tumour mutation burden (TMB)? This would be important for potential immunotherapy routes (eg Keytruda/Opdivo).
The folk at CoH should be all over this stuff though anyway. Best wishes to you both.
Male 37; Melbourne, Australia.
10/2018 Dx 3.5 cm RC adenocarcinoma, 12cm from AV
Mod diff (G2), EMVI+, LVI+, PNI-
3 local LN; 4 liver mets, resectable
pT3pN1apM1a; Stage IVa. MSS, NRAS (G13R)
CEA: Oct-18= 12; Nov-18= 14, Mar-19= 2.4, Aug-19 <2.0
11/18 - FOLFOX x 6
3/19 - Liver resection
4-5/19 - 25 x pelvic radiation w Xeloda; complete metabolic response (TRG 3)
07/19 - ULAR (robotic), temp ileo, 1/27 LN
08/19 - Missed a liver spot; to resect with reversal after adjuvant chemo
08/19 - FOLFOXIRI x 4